Article
Cardiac-targeted rAAV5-S100A1 gene therapy protects against adverse remodeling and contractile dysfunction in post-ischemic hearts
2023-03-04
Abstract excerpt
<h4>Summary</h4> Toxicity by recombinant adeno-associated viruses (rAAV) in clinical gene therapy trials (e.g., by rAAV9-mediated fatal liver failure) significantly impairs translation of preclinical rAAV-based cardiac gene therapies employing these vectors. For rAAV5 - a capsid that has shown long-term safety in clinical trials - our translational study demonstrates effective transduction of the left ventricle (...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d4395e03-3101-56c4-b2b7-772d74e069a5
- DOI
- 10.1101/2023.03.03.529004
